Avacta logo

AVCT - Avacta Share Price

18.75p 0.0  0.0%

Last Trade - 24/01/20

Sector
Healthcare
Size
Micro Cap
Market Cap £33.0m
Enterprise Value £26.5m
Revenue £4.12m
Position in Universe 1263rd / 1830
Bullish
Bearish
Unlock AVCT Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AVCT Revenue Unlock AVCT Revenue

Net Income

AVCT Net Income Unlock AVCT Revenue

Normalised EPS

AVCT Normalised EPS Unlock AVCT Revenue

PE Ratio Range

AVCT PE Ratio Range Unlock AVCT Revenue

Dividend Yield Range

AVCT Dividend Yield Range Unlock AVCT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AVCT EPS Forecasts Unlock AVCT Revenue
Profile Summary

Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

Directors
Last Annual July 31st, 2019
Last Interim July 31st, 2019
Incorporated April 29, 2003
Public Since September 8, 2003
No. of Shareholders: n/a
No. of Employees: 114
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 175,935,136
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AVCT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AVCT
Upcoming Events for AVCT
Similar to AVCT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.